To explore the complete response (CR) rate of modified short-course radiotherapy plus CAPOX and Tislelizumab versus Long-course Chemoradiotherapy plus Tislelizumab for locally advanced rectal cancer.
Age 18-75 years, any gender.
Pathologically confirmed rectal adenocarcinoma.
Baseline MR stage T3-4/N+.
Distance from anal verge ≤12cm.
Pregnant or lactating women.
Pathological diagnosis of signet ring cell carcinoma.
History of other malignancies within the past 5 years, except cured skin cancer and cervical carcinoma in situ.
Uncontrolled epilepsy, central nervous system disorders, or history of psychiatric disorders that, in the opinion of the investigator, may interfere with signing the informed consent form or affect patient compliance with oral medication.